Affimed Announces Proposed Public Offering of Common Shares
November 07 2019 - 4:11PM
Heidelberg, Germany, November 7, 2019 – Affimed N.V. (“Affimed”
or the “Company”) (Nasdaq: AFMD), a clinical stage
biopharmaceutical company committed to giving patients back their
innate ability to fight cancer, today announced that it has
commenced an underwritten public offering of its common shares. The
Company expects to grant the underwriters a 30-day option to
purchase up to an additional 15 percent of the number of common
shares sold in connection with the offering. All of the shares in
the offering will be sold by Affimed. This offering is subject to
market conditions and there can be no assurance as to whether or
when the offering may be completed, or as to the actual size or
terms of the offering.
Jefferies LLC and SVB Leerink LLC are acting as joint
book-running managers of the offering. A shelf registration
statement relating to these securities filed with the Securities
and Exchange Commission (the “SEC”) was declared effective by the
SEC on November 7, 2018. The offering will be made only by means of
a prospectus and prospectus supplement. A preliminary prospectus
supplement and accompanying prospectus related to the offering have
been filed with the SEC and are available at the SEC’s website
located at www.sec.gov. Copies of the preliminary prospectus
supplement and accompanying prospectus related to the offering may
be obtained by contacting Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, or by telephone at (877) 821-7388 or by email at
Prospectus_Department@Jefferies.com, or SVB Leerink LLC, Attention:
Syndicate Department, One Federal Street, 37th Floor, Boston, MA
02110, by telephone at (800) 808-7525, ext. 6132, or by email at
syndicate@svbleerink.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical
company committed to giving patients back their innate ability to
fight cancer. Affimed’s fit-for-purpose ROCK® platform allows
innate cell engagers to be designed for specific patient
populations. The Company is developing single and combination
therapies to treat hematologic and solid tumors.
Forward-looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to,” “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements appear in a number of places throughout
this release and include statements regarding our intentions,
beliefs, projections, outlook, analyses and current expectations
concerning, among other things, the value of our ROCK® platform,
our ongoing and planned preclinical development and clinical
trials, our collaborations and development of our products in
combination with other therapies, the timing of and our ability to
make regulatory filings and obtain and maintain regulatory
approvals for our product candidates our intellectual property
position, our collaboration activities, our ability to develop
commercial functions, expectations regarding clinical trial data,
our results of operations, cash needs, financial condition,
liquidity, prospects, future transactions, growth and strategies,
the industry in which we operate, the trends that may affect the
industry or us and the risks uncertainties and other factors
described under the heading “Risk Factors” in Affimed’s filings
with the SEC. Given these risks, uncertainties and other factors,
you should not place undue reliance on these forward-looking
statements, and we assume no obligation to update these
forward-looking statements, even if new information becomes
available in the future.
Affimed Investor and Media ContactGregory Gin,
Head of Investor RelationsE-Mail: IR@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024